SNG Stock Price: Synairgen plc has room to rally as its cure shines amid study doubting antibodies

LON: SNG has been holding its high ground around £200 per share.
A study shows COVID-19 antibodies fade in recovered patients.
Synairgen's coronavirus cure may prove more useful and timely than potential vaccines.

Rally, consolidation, and another rally? LON: SNG shares are trading around 190 pence, just under the 200 pence mark and weathering any potential downside correction or profit-taking. Synairgen made headlines – and saw its price quintupling within days – after announcing a promising cure for coronavirus.

Usage of its SNG001 drug lowered the chances of patients developing severe conditions by no less than 79%. The interferon beta medication proved highly efficient and the small British firm is already collaborating with larger ones to ramp up production.

After an increase, a fall tends to come, but there are reasons for LON: SNG's resilience. Apart from the relatively low valuation – especially when taking the magnitude of the problem into account – a cure may prove more timely than a vaccine.

Apart from the longer development time, immunization may prove temporary. According to a study published by the New England Journal of Medicine, antibodies in recovered patients fade away after an average of 73 days – less than three months.

Will buyers jump in?

Synairgen Stock Price

The chart is showing that after the leap, LON: SNG prices stabilized at a high plateau. The company is worth under £300 million, a low valuation. The 52-week high was 240 pence, but that was a temporary swing earlier this week.

It is essential to note that Synairgen made a long way from the 52-week low of 5.50 pence.

What could send the stock higher? Richard Marsen, CEO at Synairgen, said that "things are moving very quickly" when referring to the chances of its drug being approved for wide use. A seal from authorities and scaling up its production seem to keep to the next orally.

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.